Halozyme and Vertex enter global licensing deal for Hypercon™ technology across up to three targets, including $15M upfront, milestones, and royalties for concentrated biologic delivery.
Written By: Samiksha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
Halozyme Therapeutics, Inc. announced that its wholly owned subsidiary, Halozyme Hypercon, Inc., has entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals Incorporated to apply Halozyme’s Hypercon™ drug delivery technology across up to three drug targets.
Hypercon Technology Aims to Reduce Injection Volume
Hypercon™ is a microparticle-based technology designed to enable hyperconcentration of drugs and biologics. By increasing concentration, the platform reduces injection volume while maintaining the same dose. This approach may support patient-friendly administration, including potential at-home delivery of biologics.
Executive Commentary Highlights Strategic Fit
Helen Torley, President and Chief Executive Officer of Halozyme, said the agreement highlights the versatility of the Hypercon platform for enabling small-volume, patient-delivered biologics. She noted that Vertex’s expertise in developing therapies for serious diseases could help expand access to targeted biologics using the technology.
Mark Bunnage, Executive Vice President and Chief Scientific Officer at Vertex, stated that adding Hypercon to the company’s drug delivery capabilities could support development of transformative therapies. He added that Vertex plans to explore the technology across selected programs.
Financial Terms and Scope
Under the agreement, Vertex receives an exclusive license to use Hypercon technology for up to three targets. Halozyme will receive a $15 million upfront payment and is eligible for additional development and commercial milestone payments. The company will also earn royalties on net sales of any products developed using the Hypercon platform.
The collaboration expands Halozyme’s drug delivery partnerships while providing Vertex with a technology designed to enable concentrated biologic formulations and potentially more convenient administration.
Reference
Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology, 07 April 2026, https://ir.halozyme.com/news/news-details/2026/Halozyme-Announces-Global-Collaboration-and-License-Agreement-with-Vertex-Pharmaceuticals-for-Hypercon-Technology/default.aspx
About the Writer
Samiksha Vikram Jadhav is a B.Pharm graduate with a strong academic foundation in pharmaceutical sciences, pharmacology, and drug development. She has a keen interest in healthcare advancements, clinical research, medical writing, and emerging therapies. Her work focuses on presenting developments in the pharmaceutical and healthcare sectors through clear and accurate scientific communication.